Xience V making strides
This article was originally published in The Gray Sheet
Executive Summary
Guidant's everolimus-eluting stent has received a CE mark and will launch in the European Union by June , the company announced Jan. 30. Built on the firm's Multi-Link Vision stenting platform, the Xience V system is being evaluated in the SPIRIT III trial in the U.S. and Japan, with more than 70% of U.S. enrollment complete, the company says...
You may also be interested in...
Weird Xience: Abbott Will Launch The Guidant Stent Before Boston Scientific
Boston Scientific plans to launch the Xience drug-eluting stent three months after the same stent is introduced by licensing partner Abbott, giving Abbott a short-term sales advantage
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.